bcg2 Health and Spitfire have snaffled a couple more Pfizer brands, after the two combined forces to win the haemophilia treatments pitch for the Xyntha and BeneFIX products in the Australian market against two Aussie agencies. This win adds to the New Zealand haemophilia business that was won in November last year.General manager of bcg2 Health, Stuart Ogden, said the two agencies worked together to provide “a perfect blend of specialist healthcare knowledge and communication skills, combined with specialist digital strategy and production”.
“It’s great to gain even more traction in this market on the strengths of our efforts in New Zealand, as we further establish ourselves as healthcare communication specialists across the Tasman.”
“We see the healthcare markets really embracing digital technology,” says John Madden, creative director from Spitfire, ‘a creative agency with digital at the core of the business’. “It allows us to connect healthcare professionals with their patients in ways that add value to the relationship and feels intuitive to users. Working closely with the bcg2 Health team is proving to be incredibly valuable.”
Over the past seven months, bcg2 Health has pitched and won two other campaigns from Pfizer’s New Zealand Speciality Care Division. The first is a campaign for Prevenar 13, an infant vaccine for pneumococcal disease and the second is Enbrel, which is used to treat Rheumatoid Arthritis and Psoriasis. These were in addition to being awarded Pfizer’s Avigra in April.
As well as new business, bcg2 Health also has a new human after hiring Helen Purcell, a specialist healthcare group account director (managing director Sarah Norrie departed in March and is now working on the Labour party’s campaign).
Purcell is a recent arrival from New York, where she worked in the pharmaceutical communications area for the previous sixteen years at leading agencies like Y&R, Ogilvy and Grey. With prior experience working on Pfizer brands in the USA Helen will be responsible for Pfizer New Zealand business and the haemophilia portfolio in Australia.
